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Objectives: This study characterizes the changes in the pharma-
cokinetics of phenobarbital associated with extracorporeal mem-
brane oxygenation treatment in neonates, to illustrate our findings 
and provide guidance on dosing.
Design: Retrospective pilot population pharmacokinetic analysis.
Setting: Neonatal ICU.
Patients: Thirteen critically ill neonates (birth body weight, 3.21 kg 
[2.65–3.72 kg]; postnatal age at start of treatment: 2 d [0–7 d]; 
gestational age: 38 wk [38–41 wk]) receiving venovenous or 
venoarterial extracorporeal membrane oxygenation.
Interventions: Phenobarbital administered in a loading dose of 
7.5 mg/kg (8.5–16 mg/kg) and maintenance dose of 6.9 mg/kg/d 
(4.5–8.5 mg/kg/d).
Measurements and Main Results: Therapeutic drug monitoring 
data were available, yielding 5, 31, and 19 phenobarbital con-
centrations before, during, and after extracorporeal membrane 
oxygenation, respectively. Population pharmacokinetic analysis 
was performed using NONMEM 7.3.0 (ICON Development Solu-
tions, Ellicott City, MD). Maturation functions for clearance and 
volume of distribution were obtained from literature. In a one-com-
partment model, clearance and volume of distribution for a typ-
ical neonate off extracorporeal membrane oxygenation and with a 
median birth body weight (3.21 kg) at median postnatal age (2 d) 
were 0.0096 L/hr (relative se = 11%)) and 2.72 L (16%), respec-
tively. During extracorporeal membrane oxygenation, clearance 
was found to linearly increase with time. Upon decannulation, 
phenobarbital clearance initially decreased and subsequently 
increased slowly driven by maturation. Extracorporeal membrane 
oxygenation-related changes in volume of distribution could not 
be identified, possibly due to sparse data collection shortly after 
extracorporeal membrane oxygenation start. According to the 
model, target attainment is achieved in the first 12 days of ex-
tracorporeal membrane oxygenation with a regimen of a loading 
dose of 20 mg/kg and a maintenance dose of 4 mg/kg/d divided in 
two doses with an increase of 0.25 mg/kg every 12 hours during 
extracorporeal membrane oxygenation treatment.
Conclusions: We found a time-dependent increase in pheno-
barbital clearance during the first 12 days of extracorporeal 
membrane oxygenation treatment in neonates, which results in 
continuously decreasing phenobarbital exposure and increases 
the risk of therapeutic failure over time. Due to high unexplained 
variability, frequent and repeated therapeutic drug monitoring 
should be considered even with the model-derived regimen. 
(Pediatr Crit Care Med 2020; 21:e707–e715)
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Extracorporeal membrane oxygenation (ECMO), also known as extracorporeal life support, is a procedure providing life support in severe but potentially reversible 
cardiorespiratory failure in patients with a predicted chance 
of long-term survival less than 20% (1). As of July 2018, over 
100,905 patients have been treated with ECMO worldwide, in-
cluding 40,446 neonates (2). Most neonatal cases treated with 
ECMO have a primary respiratory diagnosis (viral or bacterial 
pneumonia and acute respiratory distress syndrome), while 
the remainder of cases have a primary cardiac diagnosis (car-
diopulmonary resuscitation, cardiomyopathy, cardiomyositis, 
postcardiothoracic surgery) or sepsis (3).DOI: 10.1097/PCC.0000000000002402
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Pharmacotherapy of critically ill pediatric patients on 
ECMO is complicated because it is influenced by many factors. 
Generally, volume of distribution is increased between 5% and 
400% for most drugs, whereas clearance can be decreased or 
increased compared with patients who are not on ECMO (1). 
Increase in the volume of distribution principally results from 
the added blood volume necessary to fill the ECMO circuit (3, 
4). Furthermore, a systemic inflammatory response, either re-
lated to the patient’s clinical condition and/or triggered by the 
ECMO system, downregulates cytochrome P450 enzymes, may 
result in reduced clearance of drugs cleared by these enzymes 
(3, 4). Changes in the pharmacokinetics of drugs may also be 
attributed to the drug adsorption, sequestration, and inactiva-
tion by the circuit components (3). The degree of drug adsorp-
tion to the ECMO circuit is highly variable and depends on 
drug properties, circuit type and age, and the clinical state of 
the patient (4–6). The physicochemical properties of the com-
pound, such as molecular size, lipophilicity, and plasma pro-
tein binding, determine the interaction of an individual drug 
with the ECMO circuit (7). For that reason, the investigation of 
pharmacokinetics of individual drugs during ECMO is needed 
to provide optimal dosing recommendations for the patients 
receiving ECMO.
Phenobarbital is one of most frequently administered anti-
convulsive drugs in pediatric patients due to its well-estab-
lished efficacy, the availability of an injectable dosage form, and 
its additional beneficial sedative effect (8). Monitoring serum 
phenobarbital concentrations is often routinely performed to 
achieve safe and effective individual therapy (9, 10). Despite its 
widespread use, there is insufficient information on the poten-
tial impact of ECMO on the pharmacokinetics of phenobar-
bital. Therefore, the aim of this pilot study is to characterize 
the pharmacokinetics of phenobarbital in neonatal patients 
undergoing ECMO. Model-based simulations are used to il-
lustrate the implications our findings may have on dosing in 
neonates treated with ECMO.
MATERIALS AND METHODS
Study Design
Therapeutic drug monitoring (TDM) data which were col-
lected between October 2010 and May 2018 in the neonatal 
ICU of the General University Hospital in Prague were used for 
developing a population pharmacokinetic model for pheno-
barbital in neonatal patients undergoing ECMO therapy. The 
ECMO therapy was performed by ECMO system consisting 
of an ECMO pump (Maquet Rotaflow, Rastatt, Germany and 
for one patient Medos, Stolberg, Germany), coating cannulas 
(Avalon, Boyle, Ireland or Origen, Austin, TX), and oxygenator 
(Maquet pediatric Quadrox iD, Rastatt, Germany). The cir-
cuit was primed with 250 mL of blood. Approval of the study 
was provided by the Ethics Committee of the Department of 
Ethics, General University Hospital in Prague under the RV-
project 64-165/2012. At admission, the patients’ parents signed 
an informed consent wherein they agree that anonymous data 
can be used for research and publication of the research results.
Patients were included in the study if they were neonates 
(0–28 d of postnatal age [PNA]), received phenobarbital, and 
had one or more serum phenobarbital concentration measures 
while undergoing ECMO. Patients were excluded if they were 
on dialysis, had severe congenital abnormalities, intracranial 
hemorrhage, or severe bleeding due to disseminated intravas-
cular coagulopathy.
Phenobarbital Dosing
Phenobarbital was administered as prescribed by the treating phy-
sician. In this study cohort of 13 neonates, two patients received 
phenobarbital for neuroprotection, while 11 patients received 
phenobarbital as a sedative drug of whom three were treated for 
withdrawal symptoms, two had opioid and benzodiazepine tol-
erance, and the remaining six were treated with phenobarbital 
as a part of combined analgosedation. Phenobarbital (Phenobar-
bitalum Natricum; Desitin Arzneimittel GmbH, Hamburg, Ger-
many) was dosed with a median IV loading dose (LD) of 7.5 mg/
kg (interquartile range [IQR], 8.5–16 mg/kg) administered in 15 
minutes; another LD could be given if clinically indicated until a 
maximum total LD of 40 mg/kg was reached. An IV maintenance 
dose (MD) of 6.9 mg/kg (4.5–8.5 mg/kg) a day was divided in 
two doses every 12 hours administered in 15 minutes (11). Dose 
adjustments were based on clinical and/or amplitude-integrated 
electroencephalography response. The duration of phenobar-
bital treatment was 134 hours (83–516 hr).
Bioanalytical Assay
Blood samples were taken from the arterial line. Serum was 
separated by centrifugation (1,500 × g, 15 min) and immedi-
ately used for phenobarbital level determination. Total phe-
nobarbital concentrations were measured by fluorescence 
polarization immunoassay (TDxFLx Phenobarbital Abbott 
laboratories, Diagnostics Division, Abbott Park, IL) at the bi-
ochemical laboratory of the Department of clinical biochem-
istry and microbiology, General University Hospital, the first 
Faculty of Medicine of Charles University (12). Fluorescein-
labeled phenobarbital binds an antibody and the emitted light 
is polarized due to the reduction in freedom of rotation. When 
phenobarbital is present in the patients’ serum samples, it 
reduces the extent of fluorescence polarization. The test range 
of the assay was 1.87–61.60 mg/L. Coefficient of variation of 
intra-assay was less than 7%.
Population Pharmacokinetic Analysis
The data analysis was performed using NONMEM Version 
7.3.0 (ICON Development Solutions, Ellicott City, MD) and 
PsN v3.4.2 (13, 14) both running under Pirana 2.9.0 (15). 
R 3.3.2 was used for the visualization of the data and model 
diagnostics.
Model development was performed in three steps.
1) Development of structural and statistical model: For 
the structural model, one and two-compartment mod-
els were tested to describe the distribution of phenobar-
bital. First-order clearance of phenobarbital was assumed. 
Log-normally distributed inter-individual variability terms 
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with estimated variance were tested on each pharmacoki-
netic parameter. Proportional, additive, and combination 
error models were tested for the residual error model.
2) Covariate analysis: During prolonged ECMO treatment, 
the impact of maturation, disease progression or clinical 
recovery, and ECMO treatment on phenobarbital phar-
macokinetics cannot be distinguished from each other. 
Therefore, maturation functions from a previously pub-
lished model in patients with an overlapping age-range 
that did not receive ECMO treatment (16) were included 
in the model a priori. These maturation functions are 
based on birth body weight (bBW) and PNA for clear-
ance and on actual body weight (BW) for volume of dis-
tribution. Since BW measurements during ECMO are 
not feasible, last BW measured before start of ECMO 
was used as covariate value for volume of distribution 
throughout the duration of ECMO.
After incorporation of the maturation functions, the re-
maining impact of disease progression or clinical recovery and 
ECMO treatment were evaluated by testing covariates related 
to the following variables:
• Disease status: Laboratory values, including serum cre-
atinine, serum urea, serum albumin, total bilirubin and 
direct bilirubin, C-reactive protein, blood pH, aspartate 
transaminase, and alanine transaminase, as well as urine 
output, were tested as continuous covariates;
• Concomitant therapy: Use of diuretics, inotropes, and 
therapeutic hypothermia as well as use of continuous 
renal replacement therapy were tested as categorical 
covariates;
• ECMO: On/off ECMO, ECMO modalities (venovenous, 
venoarterial), and change of ECMO circuit were tested 
as categorical covariates and duration, speed, flow, time 
after start and stop of ECMO were tested as continuous 
covariates.
For all continuous covariates, multiple time-varying mea-
surements were available. A stepwise covariate modeling pro-
cedure was performed. Continuous covariates were tested in 
linear and power functions. Categorical covariates were tested 
by estimating the parameter value for one category as a frac-
tion of the parameter value for the other category.
For model selection, a decrease in objective function of 
more than 3.84 points between nested models (p < 0.05) was 
considered statistically significant, assuming a chi-square test-
distribution. Additional criteria for model selection were rela-
tive se (Rse) of the estimates of structural model parameters 
less than 50%, condition number less than 1,000, physiologic 
plausibility of the obtained parameter values, and absence of 
bias in goodness-of-fit (GOF) plots.
3) Validation of the final model: To evaluate the robustness 
of the model and identify potential influential individu-
als, a jackknife analysis was performed, by excluding one 
patient from the dataset at a time and reestimating all 
model parameters in the final model.
The predictive properties of the structural and statistical 
model were validated using normalized prediction distribu-
tion errors (NPDEs). For this, the dataset was simulated 500 
times, after which the observed concentrations were compared 
with the range of simulated values using the NPDE package 
developed for R (R Foundation for Statistical Computing, 
Vienna, Austria; http://www.R-project.org) (17).
Model-Derived Dosing Implications
To illustrate the implications of our findings, simulations were 
performed with the final population pharmacokinetic model, 
which included inter-individual variability in model param-
eters, to evaluate the probability of target attainment. As no 
target concentration has yet been defined for neonates treated 
with phenobarbital for sedation and neuroprotection, target 
concentrations for neonatal seizures (15–40 mg/L) (18) were 
used. One-thousand simulations for newborns with a bBW of 
3.21 kg and ages of: 0, 7, 14, 21 days were performed for a LD 
of 20 mg/kg and different MD. For MD, simulations included 
a dose of 5 mg/kg/d for neonates of PNA = 0–14 days and a 
dose of 6 mg/kg/d for neonates of PNA = 15–28 days divided in 
two daily doses, which is recommended by the Dutch National 
Children’s Formulary (18) and a dosing regimen starting with 
the recommended dose with a time-dependent increase pro-
portional to the increase in clearance in the final model. The 
latter dosing regimen achieved target concentrations attain-
ment in the simulated individuals. In the simulations, simulta-
neous start of ECMO and phenobarbital therapy was assumed. 
A maximum ECMO duration of 12 days was simulated, as a 
longer duration is not supported by the model.
RESULTS
Patient Population and Data
Thirteen patients (seven male and six female) (median [IQR] 
bBW: 3.21 kg [2.65–3.72 kg], PNA at start of treatment: 2 d [0–
7 d], and GA: 38 wk [38–41 wk]) were included in the analysis. 
Demographics and treatment details are presented in Table 1.
In total, 55 phenobarbital concentrations (five concentra-
tions before ECMO, 31 during ECMO, and 19 concentrations 
after ECMO) were included in the analysis. The median number 
of blood samples per patient was 2 (1–8.5). Phenobarbital lev-
els ranged between 2.8 and 56.4 mg/L. Supplementary Figure 
1 (Supplemental Digital Content 1, http://links.lww.com/PCC/
B350) shows the phenobarbital concentrations plotted against 
time after the first dose.
Population Pharmacokinetic Model
Observed phenobarbital plasma concentrations were best 
described by a one-compartment model with log-normally 
distributed intra-individual variability (IIV) on clearance and 
volume of distribution. An additive residual error model pro-
vided the best description of residual variability.
For the covariate model, it was first confirmed that the 
covariate relationships obtained from literature to describe 
the maturation of clearance and volume of distribution of 
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phenobarbital, led to accurate predictions of phenobarbital 
concentrations obtained prior to the start of ECMO. This was 
indicated by the lack of bias in GOF plots for these samples 
and by the fact that all conditional weighted residuals values 
were between –2 and +2, which is the range where 95% of the 
observations are expected to be found.
Inclusion of ECMO as a binary covariate (i.e., on/off) on 
clearance resulted in a statistically significant improvement 
of the model fit (p < 0.001). Adding time since the start of 
ECMO in a linear relationship as a covariate on clearance, fur-
ther improved the fit (p < 0.001). The estimation of an expo-
nential increase in clearance over time since start of ECMO 
did not statistically significantly improve the model fit further, 
therefore the linear relationship was retained in the model. 
After inclusion of this covariate relationship, none of the other 
covariates were statistically significant.
The final parameter estimates are presented in Table 2  
and the final model code will be made available in the Drug 
Disease Model Resources model repository (http://reposi-
tory.ddmore.eu/). In the final model, clearance and volume 
of distribution for a typical neonate of the median bBW of 
3.21 kg at the median PNA of 2 days that was off ECMO were 
0.0096 L/hr (Rse = 11%)) and 2.72 L (16%), respectively. To 
illustrate the impact of ECMO on phenobarbital pharmaco-
kinetics: these parameters for this typical neonate 1 day after 
TABLE 1. Clinical Characteristics of the 
Patients Included in This Analysis
Parameter (Unit) Valuea
Age (d) at the start of ECMO treatment 2 (0–7)
Gestational age (wk) 38 (38–41)
Birth bodyweight (kg) 3.21 (2.65–3.72)
Body weight (kg) at the start of ECMO 
treatment
3.23 (2.67–3.72)
Sex, male/female, n (%) 7/6 (54/46)
Survival, n (%) 8 (61.5)
Phenobarbital use
 Loading dose (mg/kg) 7.5 (8.5–16)
 Maintenance dose (mg/kg/d) 6.9 (4.5–8.5)
 Duration of treatment (hr) 134 (83–516)
Primary indication for ECMO, n (%)
 Respiratory failure 10 (76.9)
 Persistent fetal circulation 1 (7.7)
 Sepsis 1 (7.7)
 Congenital diaphragmatic hernia 1 (7.7)
Laboratory values at the start of treatment
 Creatinine (μmol/L) 61 (43–63)
 Urea (mmol/L) 12 (2.3–25)
 Total bilirubin (μmol/L) 58 (38–146)
 Direct bilirubin (μmol/L) 4 (1–59)
 Albumin (g/L) 31 (26–35)
 C-reactive protein (mg/L) 14 (0–29)
 Aspartate transaminase (IU/L) 1.2 (0.70–2.7)
 Alanine transaminase (IU/L) 0.45 (0.23–0.74)
 pH 7.38 (7.35–7.45)
 Urine output before ECMO start (mL/kg/hr) 5.3 (2.9–5.9)
 Urine output during ECMO (mL/kg/hr) 6.5 (4.8–7.7)




 Length (hr) 109 (50–204)
 Venovenous modality, n (%) 1 (7.7)
 Venoarterial modality, n (%) 11 (84.6)
 Venovenous–venoarterial modality, n (%) 1 (7.7)
 Circuit change, n (%) 2 (15.4)
 ECMO flow (L/min) 0.35 (0.25–0.45)
 ECMO speed (revolutions/min) 2,340 (2,075–2,620)
Concomitant treatments, n (%)
 Diuretics 13 (100)
 Inotropes 13 (100)
 Continuous renal replacement therapy 1 (9)
 Therapeutic hypothermia 2 (18)
ECMO = extracorporeal membrane oxygenation, IU = international units.
a Values are presented as median (interquartile range) unless stated otherwise.
TABLE 2. Parameter Estimates of the Final 
Model
Parameter (Units) Final Model (Rse %)
Fixed effects
 CL (L/hr) = CLp × (1 + θbBWCL × [bBW–2.59]) × (1 + 
θAGE × [AGE–4.50]) × (1 + θTE × [TE/109])ECMO_on
  CLp (L/hr) 0.0096 (11%)
  θbBWCL 0.369 FIX
  θAGE 0.0533 FIX
  θTE 1.09 (28%)
 Vd (L) = Vp × (1 + θBWV × [BW–2.70])
  Vp (L) 2.72 (16%)
  θBWV 0.309 FIX
Inter-individual variability
 CL (%) 29.4% (26%)
 Vd (%) 45.3% (17%)
Residual variability
 Proportional (%) 4.41 (32%)
bBW = birth body weight, BW = body weight, CL = clearance, CLp = 
population clearance value, ECMO_on = binary parameter indicating whether 
extracorporeal membrane oxygenation treatment is on (1) or off (0), FIX = fixed, 
Rse = relative se of the estimate, Vd = volume of distribution, Vp = population 
volume of distribution value, θAGE = increase in clearance per postnatal day, 
θbBWCL = increase in clearance per kg birthweight, θBWV = increase in 
volume of distribution per kg actual bodyweight, ΘTE = increase in clearance 
per hr time after extracorporeal membrane oxygenation cannulation (TE).
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start of ECMO are 0.011 L/hr and 2.72 L, respectively, and 
after 10 days of ECMO treatment, the parameter values are 
0.033 L/hr and 2.72 L, respectively.
The model findings regarding the changes of phenobarbital 
clearance during ECMO are graphically illustrated in Figure 1, 
in which clearance for a typical individual (BW = 3.21 kg, 
PNA at start of ECMO = 2 d) through the course of time is 
depicted. Before and after ECMO, the clearance of phenobar-
bital increases slowly as the neonates mature. On top of this, 
clearance increases linearly with time during ECMO. After 
decannulation, phenobarbital clearance was found to decline 
rapidly to the values expected based on the age and weight of 
the neonate (Fig. 1).
Although the number of individuals in our analysis and 
the number of observations per individual were small, the 
data are sufficiently informative to support estimation of the 
model parameters which is indicated by the condition number 
of 49.42 (< 1,000). The precision of the estimated parameter 
values is also acceptable, with Rse values around or below 30%. 
The basic GOF plots in Figure 2 indicate that the final model 
can describe the data accurately, as the predicted population 
and predicted individual concentrations are described without 
bias before, during, and after ECMO treatment.
The distribution of the NPDEs obtained with the model for 
the dataset has a mean of –0.0799 and variance of 1.034. Neither 
of these values are significantly different from the expected values 
of 0 (p = 0.53) and 1 (p = 0.56), respectively (Supplementary 
Fig. 2, Supplemental Digital Content 1, http://links.lww.com/
PCC/B350). This indicates that predictions regarding the struc-
tural model and the variability in the data are accurate.
Small deviations in parameter values are always to be ex-
pected with the exclusion of individuals from the model fit in 
a jackknife procedure, due to differences in number of sam-
ples, sampling times and dosing between individuals and due 
to differences in range or distribution of covariate values that 
are introduced when removing an individual from a dataset. 
The structural parameter estimates from the jackknife samples 
were however all within ±10% of the estimates obtained in the 
original model fit. The only exception was noted for the esti-
mate of volume of distribution (+13%) when patient 6 was 
excluded. For the IIV parameters, a maximum difference of 
–19.5% was noted, when patient 1 was excluded. The param-
eters in the covariate relationship describing the increase in 
clearance over time after ECMO cannulation from the jack-
knife samples were all within ±15% of the covariate parameter 
of the original dataset, apart from one sample leading to a dif-
ference +22%, which was observed for patient 1. We did not 
identify any deviating patient characteristics for patients 1 and 
6. As there are overall only small deviations in obtained param-
eter values with the exclusion of individuals from the dataset, it 
can be concluded that no individuals with a large influence on 
estimated parameter values were present.
Model-Derived Dosing Implications
The simulations of the current dosing regimen (LD of 20 mg/
kg and a MD of 5 mg/kg/d for neonates of PNA = 0–14 d and 
6 mg/kg/d for neonates of PNA = 15–28 d divided in two daily 
doses) in Figure 3A shows high IIV in pharmacokinetics of 
phenobarbital during ECMO treatment, as reflected in the 
wide 95% prediction interval. Furthermore, the simulations 
also indicate that the applied recommended MD leads to an 
increasing number of neonates being under-dosed over time 
when they are on ECMO treatment.
As clearance is the driver of steady state concentration, 
and therefore also of MD, the 
model suggests that optimal 
dosing will be achieved by a 
regimen that includes a MD 
starting with 4 mg/kg/d that 
is increasing with 0.25 mg/kg 
every 12 hours during ECMO 
treatment. Figure 3B illustrates 
the simulated concentration-
time profiles for the same indi-
viduals with the model-derived 
dosing regimen. Overall, these 
results suggest that more neo-
nates will be dosed adequately, 
and therefore, less dose adjust-
ment will be necessary when 
this dosing regimen is followed. 
However, as the 95% predic-
tion interval of simulated con-
centrations is still outside of 
the therapeutic range, TDM is 
still warranted. When ECMO 
stops, phenobarbital clearance 
returns back to the value that is 
Figure 1. Predicted clearance values for a typical individual (body weight = 3.21 kg, postnatal age = 2 d at the 
start of treatment) through the course of time. The figure represents a patient being on phenobarbital therapy: a 
week before extracorporeal membrane oxygenation (ECMO) initiation (1), then 12 d on ECMO (2), and a week 
after ECMO cessation (3).
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expected based on maturation only, meaning that “normal” rec-
ommended dosing should be applied again after decannulation.
DISCUSSION
This is the first study using a population pharmacokinetic 
approach to describe the pharmacokinetics of phenobarbital 
in critically ill neonates undergoing ECMO. As the number of 
critically ill neonates requiring ECMO is small, it is difficult to 
include a sufficient number of patients in studies in this popu-
lation; however, population modeling allows for the gain of as 
much information from these data as possible, as it can handle 
sparse and unbalanced data (19). Our analysis showed a time-
dependent increase of phenobarbital clearance during ECMO 
treatment. Additionally, we could not identify an influence of 
ECMO on volume of distribution of phenobarbital. Our popu-
lation pharmacokinetic study with its limited sample size repre-
sents the first step toward understanding the pharmacokinetic 
characteristics of phenobarbital in neonates undergoing ECMO 
and provides guidance for dosing strategies in these patients.
It is known that the influence of maturation, disease pro-
gression or clinical improvement, and ECMO treatment on 
phenobarbital pharmacokinetics cannot be differentiated from 
each other during prolonged ECMO treatment. Therefore, 
maturation functions from a previously published model in 
patients with an overlapping age-range that did not receive 
ECMO treatment (16) were included in the model. First, it 
was confirmed that inclusion of these maturation functions to 
the model led to accurate predictions of phenobarbital con-
centrations obtained prior to the start of ECMO and after the 
Figure 2. Goodness-of-fit plots for the final model of phenobarbital pharmacokinetics in neonates on extracorporeal membrane oxygenation (ECMO). 
A, Population predicted phenobarbital concentration versus observed phenobarbital concentration. B, Individual predicted phenobarbital concentration 
versus observed phenobarbital concentration. C, Conditional weighted residuals (CWRES) versus time after dose. D, CWRES versus population predicted 
concentration.
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ECMO cessation. This indicated that the patients off ECMO 
and the patients from the previously published model were 
comparable regarding the maturational status of the pharma-
cokinetics of phenobarbital. Values of clearance during ECMO 
were found to be increased and this increase was time-depen-
dent. Although the number of patients and obtained samples 
was small, diagnostics and validation of the model indicate 
that the data support the findings in the final model.
Apart from improved organ perfusion and oxygenation 
with extracorporeal support and potential clinical improve-
ment over time, other factors may account for the increase in 
clearance values during ECMO. In the first place, the transit 
of blood through the ECMO circuit may result in degradation 
and/or sequestration of administered drugs (20). Sequestration 
of drugs in ECMO circuits is a well-known, but unpredict-
able phenomenon which depends on many factors. Lipophilic 
drugs have shown a greater tendency for drug sequestration 
compared with hydrophilic drugs (6, 20). Additionally, seques-
tration may increase with increasing plasma protein binding 
(5, 20). With a log P of 1.47 and 25–40% protein binding one 
could anticipate phenobarbital sequestration to be moderate 
(21). Literature regarding adsorption of phenobarbital to 
ECMO circuit is very sparse: the only in vitro study from 1993 
showed higher losses of phenobarbital in a new circuit (17%) 
compared with the clinically used circuit (6%) (22).
Clearance in our study increased linearly during ECMO, 
reaching more than three times increase during 12 days of 
ECMO. This increase is expected to eventually reach a plateau, 
but this was not observed during the duration of the current 
study. Kleiber et al (23) reported a time-dependent increase 
in the clearance of clonidine in a pediatric population during 
ECMO treatment. Clonidine is a drug with physicochemical 
properties similar to phenobarbital (21). The increase in cloni-
dine clearance during ECMO was described with a sigmoidal 
function reaching the maximum clearance around 18–20 days 
after the start of ECMO treatment. Given that the duration 
of treatment for the individuals included in this analysis was 
maximum 12 days, it is possible that this was too short for the 
plateau in maximum clearance increase to be observed. This 
does imply, however, that findings in the current study should 
not be extrapolated beyond 12 days of ECMO treatment.
Interestingly, we found no changes in volume of distribu-
tion of phenobarbital during or after ECMO. Many previous 
studies showed an increase of volume of distribution for 
drugs during neonatal ECMO (5, 24). There are two impor-
tant factors potentially contributing to increase of volume of 
distribution by ECMO: the hemodilution due to circuit prim-
ing, and capillary leakage and fluid retention due to a sys-
temic inflammatory response, either related to the patient’s 
clinical condition or triggered by the ECMO (24). Generally, 
Figure 3. Simulated phenobarbital concentration over time represented as median with 95% prediction intervals, for 1,000 neonates with a birthweight 
of 3.21 kg and a postnatal age (PNA) at start of treatment of 0, 7, 14, and 21 d, with simultaneous start of extracorporeal membrane oxygenation (ECMO) 
and phenobarbital therapy at time = 0. The following dosing regimens were simulated: (A) current dosing regimen (loading dose [LD] = 20 mg/kg;  
maintenance dose [MD] = 5 mg/kg/d for neonates of PNA = 0–14 d and 6 mg/kg/d for neonates of PNA = 15–28 d divided in two daily doses);  
(B) new model-derived regimen (LD = 20 mg/kg, start with MD = 4 mg/kg/d with 0.25 mg/kg increase every 12 hr during ECMO treatment).
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volume of distribution increases rapidly at the start of ECMO 
and then remains unchanged (24). It is possible that sparse 
data collection at early time points after ECMO initiation 
prevented the observation of changes in volume of distribu-
tion of phenobarbital in the current study.
To illustrate the implications the findings of our model have 
for phenobarbital dosing in neonates on ECMO, model-based 
simulations were performed. Median and 95% prediction in-
terval for simulated concentrations were compared with target 
concentrations for neonatal seizures (15–40 mg/L), as target 
therapeutic concentrations for sedation and neuroprotection 
are still lacking (18). From the results, it seems that current rec-
ommended MD (5 mg/kg/d for neonates of PNA = 0–14 d and 
6 mg/kg/d for neonates of PNA = 15–28 d) is not appropriate 
for older neonates and neonates being on ECMO for a longer 
time. The model suggests, and simulations confirm, that more 
optimal dosing will be achieved by a regimen that includes a 
MD starting with 4 mg/kg/d that increases with 0.25 mg/kg 
every 12 hours during ECMO treatment. It should be noted 
that findings with our model only apply to the first 12 days 
of ECMO therapy, considering that the length of treatment 
for the patients included in this study was maximum of 12 
days. Additionally, the model-derived dosing regimen assumes 
target concentrations obtained for neonatal seizures, while 
other indications may require different targets. Furthermore, 
the dosing guidance only takes into account adjustments based 
on pharmacokinetic considerations and does not take the im-
pact of potential changes in the pharmacodynamics or safety 
aspects during ECMO treatment into account. Finally, as this 
report represents a pilot study with a limited number of sam-
ples and patients, our results need to be confirmed in future 
trials.
Given the large variability in pharmacokinetics of pheno-
barbital in neonates on ECMO (Fig. 3), still not all patients will 
be optimally treated by the model-derived regimen as indi-
cated by parts of the 95% prediction interval of simulated con-
centrations being outside of the therapeutic range. Therefore, 
TDM should still be considered in individual cases, even with 
the model-derived regimen. Monitoring of the plasma concen-
trations should also be repeated over time, as the simulations 
show that patients that once had adequate phenobarbital ex-
posure could at later time points get to overexposure or un-
derexposure. This especially applies for the neonates in which 
ECMO is initiated on the first day of life. Finally, we would 
like to stress that population pharmacokinetic models are lim-
ited to the drug and patient population used in the analysis. 
Therefore, new analyses would be required for new drugs. The 
ability of population models to deal with sparse and unbal-
anced data would make this approach ideally suitable for such 
future analyses.
CONCLUSIONS
Our results indicate that that the current recommended phe-
nobarbital MD may not be appropriate for neonates of PNA 
greater than 7 days being on ECMO for at least 8 to 12 days. 
Time-dependent increase in phenobarbital clearance results in 
continuously decreasing phenobarbital exposure in patients 
during ECMO treatment and will thus increase the risk of 
therapeutic failure over time. This implies that continuously 
increasing doses of phenobarbital over time are needed for 
these patients. Due to high remaining unexplained variability, 
repeated TDM over time should still be considered.
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